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Abstract
Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not lose the major molecular
response (MMR) after stopping treatment with tyrosine kinase inhibitors (TKI). This strategy is safe in clinical trials, but
its applicability in the real-life setting remains unsettled. We describe the outcomes after TKI discontinuation in a
nationwide series of 236 CML patients. Median follow-up from treatment discontinuation was 21.5 months and 5
patients died from CML-unrelated causes. TKI therapy was reinitiated due to MMR loss (n= 52), increase ≥ 1 log in BCR-
ABL transcript level without losing MMR (n= 12), patient preference (n= 2), and withdrawal syndrome (n= 1).
Treatment-free remission rate at 4 years was 64% (95% confidence interval, CI: 55%–72%). Cumulative incidence of
molecular recurrence at 3 years was 33% (95% CI: 26%–38%). TKI treatment for < 5 years and MR4.5 duration shorter
than 4 years were both associated with higher incidence of molecular recurrence. No patient had disease progression.
Response status at last control was: MR4.5 (n= 196), MR4 (n= 15), MMR (n= 14), complete cytogenetic response (n=
10), and other (n= 1). A significant increase in Hb and cholesterol levels was observed after imatinib withdrawal. Our
results demonstrate that TKI treatment discontinuation is feasible in real-life clinical practice.
Introduction
Life expectancy of patients with chronic myeloid leu-
kemia (CML) is currently approaching that of the general
population, as a result of the successful treatment with
tyrosine kinase inhibitors (TKIs)1. During the first 1 or 2
years of treatment, most patients achieve a significant
decrease in the leukemic burden to a level that protects
them from disease transformation2. Later on, about
30–50% of patients achieve a state of undetectable or
nearly undetectable molecular residual disease that is
generally sustained if treatment compliance is good3–5.
Despite such excellent efficacy, several studies have
demonstrated the persistence of leukemic stem cells in
CML patients with deep molecular response (DMR)6,7,
with this supporting the need to maintain treatment
indefinitely to prevent disease recurrence. However, mere
© The Author(s) 2018
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Juan Carlos Hernández-Boluda (hernandez_jca@gva.es)
1Hematology Department, Hospital Clínico Universitario-INCLIVA, Valencia,
Spain
2Hemotherapy and Hemostasis Department, Hospital Clínic-IDIBAPS, Barcelona,
Spain
Full list of author information is available at the end of the article.



































persistence of leukemia stem cells at such low level may
not predict disease progression or resistance. Of concern,
long-term TKI therapy is not devoid of potential medical
risks for the patients8 and poses a considerable economic
burden to the healthcare systems9, although this has been
eased with the arrival of generic imatinib.
The notion of the need of lifelong treatment in CML has
been challenged in recent years by the results of numer-
ous clinical trials demonstrating that over half of the
patients in DMR can remain relapse-free after stopping
TKI therapy10–13. Data on more than 2500 patients who
discontinued treatment in sustained DMR have demon-
strated that this approach is feasible in the setting of
controlled clinical trials 14–16. Most relapses are observed
during the first year after treatment cessation but late
relapses can occasionally occur, and therefore close
monitoring is of crucial importance for the safety of this
strategy17.
It is of note that achieving a treatment-free remission
(TFR) has quickly become a key goal of CML therapy18,19,
even though no general consensus on its applicability in
clinical practice has been established14,15,20. Moreover,
information on the safety of TKI cessation outside of
clinical trials is still limited21–24. Only recently, a number
of publications have focused on the selection of optimal
candidates for treatment cessation outside of clinical trials
and on the minimum requirements for an adequate
monitoring15,16,18,25–27. In this study, we describe the
outcomes after TKI discontinuation in a large series of
CML patients from Spain.
Methods
Patients
The present retrospective study comprised a series of
236 patients in chronic-phase CML, who discontinued
TKI treatment outside of clinical trials between April
2009 and February 2018 in 33 Spanish institutions asso-
ciated to the Grupo Español de Leucemia Mieloide Cró-
nica (GELMC). After central review, all cases met the
following inclusion criteria: (a) TKI treatment duration
for at least 3 years; (b) sustained MR4.5 (BCR-ABL1
International Scale (IS) ≤ 0.0032% or undetectable BCR-
ABL1 in samples with ≥ 32,000 ABL1 transcripts) in ≥ 4
consecutive determinations (one single point in MR4 was
acceptable) during a minimum of 2 years before treatment
discontinuation; (c) strict molecular monitoring in a
reference laboratory expressing the results on the IS with
sensitivity > 4-log. Patients who had undergone allogeneic
hematopoietic stem cell transplantation were excluded,
but other previous pharmacological therapies were
permitted.
Molecular relapse was defined as consecutively detect-
able peripheral blood BCR-ABL1 transcripts showing a ≥ 1
log increase or loss of major molecular response (MMR)
in any single sample. During the study period, both
situations could trigger TKI resumption at the discretion
of the attending physician based on the prevailing
recommendations at that time.
The study was approved by the Ethics Committee of the
Hospital Clínico Universitario of Valencia and registered
by the AEMPS (Agencia Española de Medicamentos y
Productos Sanitarios), under the reference INC-IMA-
2017–01. Informed consent for the inclusion in the study
was obtained in accordance with the requirements by
local ethics committees.
Statistical analysis
Quantitative data are expressed as median and inter-
quartile range (IQR) and qualitative data as percentages.
The non-parametric Skillings–Mack test was used for
comparing the laboratory values at baseline and at dif-
ferent time points after treatment discontinuation28. Dif-
ferences in the distribution of categorical and continuous
variables were evaluated by the χ2-test and the
Mann–Whitney U-test, respectively.
TFR was estimated by the method of Kaplan–Meier and
defined as the time from TKI discontinuation to the date
of restarting therapy for any reason or the date of last
contact if treatment was not restarted. Incidence of
molecular relapse was calculated using the cumulative
incidence function with resumption of TKI treatment in
the absence of molecular relapse and death in MMR as
competing events. For the remaining patients, follow-up
was censored at the date of the last molecular monitoring.
The following patients’ clinical characteristics were eval-
uated for their potential relationship with the incidence of
molecular relapse: sex, age at discontinuation, Sokal risk
score, type of BCR-ABL1 transcript (e13a2 vs. e14a2),
history of TKI resistance, number of TKI lines before
discontinuation (1 vs. more than one), type of TKI at the
time of discontinuation (imatinib vs. others), prior expo-
sure to interferon, aggregated time on TKI treatment, and
duration of MR4.5 before discontinuation. Optimal
prognostic cutoffs for time on TKI treatment and dura-
tion of MR4.5 before discontinuation were selected by
receiver-operating characteristic curve analysis of mole-
cular relapse at 1 year. Univariate analyses of factors
predicting molecular relapse were done within the fra-
mework of competing risks by the method of Fine and
Gray29.
All thee performed with IBM SPSS 22.0 (SPSS, Chicago,
IL, USA) and Stata 11 (https://www.stata.com).
Results
Patients’ characteristics and clinical outcome
Demographics and treatment history of the whole series
is summarized in Table 1. Median age at time of stopping
TKI treatment was 61 years (IQR: 52–72) and 123 (52%)
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patients were females. Sokal risk score at diagnosis was
high in only 17 (8%) patients. BCR-ABL transcript was
typical in 232 cases (e13a2= 70, e14a2= 104, both= 6,
p210 but undetermined isoform= 52) and atypical in 4
cases (e14a3= 1, e13a3= 1, e1a2= 2). Frontline
TKI treatment consisted of imatinib (n= 217), nilotinib
(n= 15), dasatinib (n= 2), or bosutinib (n= 2). Second-
line TKI treatment consisted of imatinib (n= 3), nilotinib
(n= 22), or dasatinib (n= 27). Third-line TKI treatment
was imatinib (n= 3), nilotinib (n= 11), bosutinib (n= 4),
or ponatinib (n= 2). At the time of stopping treatment,
most patients (74%) were receiving imatinib. All patients
were in DMR, but the main reasons for TKI cessation
were the presence of side effects or a concomitant disease
(n= 66), an attempt to achieve a TFR in the absence of
clinically relevant TKI toxicity (n= 166) and pregnancy or
planning pregnancy (n= 4).
At the study closing date in 15 May 2018, median
follow-up from treatment discontinuation was
21.5 months (IQR: 10–39) and 5 patients had died while
in MMR due to CML-unrelated causes. In 67 patients
(28%), TKI therapy was reinitiated due to molecular
relapse (loss of MMR: n= 52, increase ≥ 1 log in BCR-
ABL transcript level at two consecutive assessments
without losing MMR: n= 12), patient preference (n= 2),
and severe withdrawal syndrome (n= 1). One additional
patient lost MMR after 20 months from treatment ces-
sation but decided not to be retreated, with spontaneous
recovery of MMR in subsequent determinations. The
cumulative incidence of molecular recurrence was 20%
(95% confidence interval (CI): 16%–25%) at 6 months,
26% (95% CI: 21%–30%) at 1 year, and 33% (95% CI:
26%–38%) at 3 years (Fig. 1). Forty-nine relapses (75% of
total) occurred in the first 6 months, eight between
months 7 and 12, and eight later than 12 months. The
latest loss of MMR was detected 30 months after TKI
discontinuation. One patient restarted treatment
44 months after TKI discontinuation due to ≥ 1 log
increase in BCR-ABL1 transcripts in two consecutive
positive samples without losing MMR. The probability of
TFR at 1 and 4 years was 72.5% (95% CI: 66%–78%) and
64% (95% CI: 55%–72%), respectively (Fig. 2). Among the
164 patients who remained in MMR without treatment,
10 lost MR4.5 (without loss of MR4) and 19 lost MR4 on
at least one occasion during the follow-up period. The
aggregated time off treatment for the whole series was
4559 months.
Safety and laboratory data after TKI discontinuation
All patients remained in complete hematologic response
and none progressed to the advanced phases of CML. At
the time of restarting treatment, the median BCR-ABL1 IS
was 0.3% (IQR: 0.1–1.17), with this value being > 5% in
only seven instances. Most patients (81%) received the
same TKI that they were taking before treatment cessa-
tion. In 44 of the 52 patients (85%) who lost MMR,
treatment was initiated within the first month after
detection of the molecular relapse. Median follow-up after
treatment resumption was 20 months (IQR: 9–37).
Among the 64 patients who restarted treatment due to
molecular recurrence, 46 of 52 regained MMR after a
median time of 3 months (IQR: 1–5), 50 of 64 regained
MR4 after a median time of 3.5 months (IQR: 2–6), and
47 of 64 regained MR4.5 after a median time of 5 months
(IQR: 2–8). Six patients did not regain MMR, but the
follow-up of five of them was still short (< 3 months). The
remaining one was a heart transplantation recipient with
chronic renal failure, who was unable to maintain TKI
therapy continuously, due to several infectious episodes
and pleural effusion. At last control, the response
status was as follows: MR4.5 (n= 196), MR4 (n= 15),Fig. 1 Cumulative incidence (± 95% CI) of molecular relapse after TKI
discontinuation
Fig. 2 Treatment-free remission (± 95% CI) after TKI discontinuation
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MMR (n= 14), complete cytogenetic response (n= 10),
and other (n= 1).
A total of 51 patients (22%) developed musculoskeletal
or joint pain after treatment cessation. In one patient,
imatinib had to be reinitiated at low doses due to severe
pain and joint deformities in both hands that did not
respond to anti-inflammatory drugs.
In 66 patients in DMR, the main reason for TKI ces-
sation was the presence of side effects or a concomitant
disease. Among the 62 cases in whom evolutive data were
available, a complete resolution of such toxicity was noted
in 33 (53%) patients, a partial improvement was seen in 17
(28%) patients, whereas no significant change was
observed in the remainder.
We evaluated several hematological and biochemical
parameters at baseline and at 3 and 6 months following
TKI cessation. At the time of treatment discontinuation,
patients on imatinib had on average lower values of Hb,
leukocytes, and cholesterol, and higher creatinine levels
than patients on nilotinib, although mostly within normal
ranges (Table 2). In patients stopping imatinib, a sig-
nificant increase in the Hb levels, leukocyte counts,
total lymphocyte counts, and platelet counts was observed
(Fig. 3). At 6 months, increases in Hb levels ≥ 1 g/dL and
≥ 2 g/dL were observed in 51% and 25% of patients,
respectively. Among the anemic patients, the median Hb
increase was 1.8 mg/dL (IQR: 0.9–2.5), with 72% and 47%
of cases experiencing increases in Hb levels ≥ 1 g/dL and
≥ 2 g/dL, respectively. The serum creatinine decreased
slightly, whereas cholesterol levels showed a significant
increase (Fig. 3). Median increase in total cholesterol level
at 6 months was of 29.5 mg/dL (IQR: 12.2–41.7), with 53%
of patients with a baseline cholesterol < 200mg/dL
reaching a cholesterol level above such figure. By contrast,
discontinuation of nilotinib was not followed by any
relevant change in laboratory values, except for a mild
decrease in the leukocyte counts (data not shown). Finally,
Table 2 Evolution of the laboratory values after stopping imatinib or nilotinib
At baseline At 6 months after discontinuation
Imatinib Nilotinib P Imatinib Nilotinib P
Hb, g/dLa 12.5 (11.7–13.7) 13.5 (12.5–14.8) 0.002 13.5 (12.7–14.3) 13.6 (12.4–14.8) 0.74
Leukocytes, × 109/La 5.4 (4.5.6.9) 7.8 (6.1–9.1) < 0.001 6.5 (5.4–8) 7.25 (6.1–9.1) 0.11
Lymphocytes, × 109/La 1.8 (1.5–2.3) 2 (1.6–2.4) 0.063 2.1 (1.75–2.6) 1.85 (1.6–2.5) 0.18
Platelets, × 109/La 215 (190–257) 223 (180–269) 0.59 255 (205–286) 214 (181–271) 0.09
Creatinine, mg/dLa 0.97 (0.8–1.17) 0.86 (0.72–1.05) 0.025 0.9 (0.73–1.08) 0.89 (0.72–1.05) 0.67
Total cholesterol, mg/dLa 181 (155–203) 206 (160–238) 0.025 207 (178–232) 172 (140–210) 0.004
aMedian (interquartile range)
The Mann–Whitney U-test was used for comparisons
Numbers in bold are those with a significant P-value on the statistical analysis (P < 0.05)
Table 1 Demographics and treatment history of 236
chronic-phase CML patients who discontinued TKI
treatment in DMR in Spain from April 2009 to February
2018
Age at diagnosis, yeara 50 (40–61)
Age at TKI discontinuation, yeara 61 (52–72)
Sex, females (%) 123 (52)





Time from diagnosis to TKI discontinuation, monthsa 130 (96–162)
Prior interferon treatment, n (%) 55 (23)










History of resistance to any TKI, n (%) 17 (7)
Duration of TKI treatment, monthsa 123.5 (93–150)
Time in MR4.5 before TKI discontinuation, monthsa 68 (40–100)
DMR deep molecular response, TKI tyrosine kinase inhibitor
aMedian (interquartile range)
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the number of patients who discontinued other TKI was
too small to draw any conclusions on this subject.
Predictors of molecular relapse
Table 3 summarizes the analysis of factors associated
with increased risk of molecular relapse. As can be seen,
shorter periods of both TKI treatment and RM4.5 before
TKI discontinuation were significantly associated with
increased risk of molecular recurrence. Indeed, the
cumulative incidence of relapse at 3 years in patients who
had received TKI treatment for more than 5 years was
30% (95% CI: 24%–38%), as compared with 59% (95% CI:
38%–80%) for those treated for a shorter period (Sup-
plemental Figure S1). Patients in sustained MR4.5 for
more than 4 years before TKI cessation had a 25% (95%
CI: 18%–35%) cumulative incidence of molecular relapse
at 3 years, as compared with 46% (95% CI: 34%–59%) for
those with a shorter period in MR4.5 (Supplemental
Figure S2). Type of TKI at the time of discontinuation
(imatinib vs. others) had no effect on the subsequent risk
of molecular relapse (subhazard ratio (SHR): 0.77; 95% CI:
0.44–1.33; P= 0.35).
According to Hughes and Ross15, optimal candidates for
treatment discontinuation in clinical practice would be
those fulfilling all the following criteria: (a) patients in
chronic-phase CML, who have a low or intermediate
Sokal risk score and a typical BCR-ABL transcript (e13a2
or e14a2); (b) at least 8 years on TKI treatment without
history of resistance; and (c) sustained MR4.5 lasting ≥ 2
years. In the present series, 58% of patients fulfilled these
criteria as optimal candidates for TKI discontinuation.
However, the cumulative incidence of molecular relapse
Fig. 3 Evolution of selected analytical parameters during the first 6 months after imatinib discontinuation. *Changes in all the parameters were
statistically significant (P < 0.001) by the Skillings–Mack test
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for the optimal candidates did not significantly differ from
the “less than optimal” group (SHR: 0.85, 95% CI:
0.47–1.52, P= 0.58; Supplemental Figure S3).
Discussion
In the present study, the safety of TKI discontinuation
in clinical practice was evaluated in a nationwide series of
236 CML patients from 33 Spanish centers. Overall, the
treatment-free survival was of 64% at 4 years. Most
patients who fail to maintain TFR regained a DMR after
3–5 months of restarting treatment. No case of disease
progression was documented. These data confirm the
applicability of this treatment strategy outside of clinical
trials in Spain.
In fact, the results from the current series compare
favorably with the ~50% TFR rate reported in most clin-
ical trials on TKI discontinuation10–13. Moreover, in 18%
of our patients the reason for treatment resumption was
an increase in BCR-ABL1 transcript levels without losing
MMR. It is currently known that a proportion of such
cases, particularly those presenting an increase in BCR-
ABL1 transcript levels after the first 6 months of stopping
treatment (i.e., “the late molecular relapses”)12,17 could
have spontaneously regained DMR without therapy.
However, this information was not available at the time of
TKI cessation in our earlier cases, whereas in other
instances the decision of resuming treatment before
MMR loss might reflect the cautious approach of the
attending physicians to prevent any complication related
to stopping TKI therapy outside of a clinical trial.
Nevertheless, the favorable TFR of the current series likely
derives from the prolonged exposure to TKI treatment
(median ~10 years) and the sustained duration in DMR
(median ~5 years) before TKI discontinuation in our
patients, which largely exceeded the minimal thresholds
of clinical trials. Actually, these two variables may be the
most important factors affecting the probability of mole-
cular relapse-free survival27. In the recently published
EURO-SKI trial13, the probability of maintaining MMR at
6 months was of 61% in imatinib-treated patients with
DMR duration of more than 3.1 years, whereas it was of
44% only in those with a shorter period in DMR.
Strict molecular monitoring and a swift resumption of
TKI treatment upon detection of molecular relapse are
essential for the safety of the discontinuation strategy in
clinical practice26. To this respect, Spain has an extensive
network of certified laboratories for BCR-ABL1 molecular
monitoring in the public health system, where the great
majority of CML patients are managed. In our series, most
patients resumed TKI treatment within the first month
after detection of MMR loss. Occasionally, treatment
initiation was delayed due to an ongoing pregnancy. Of
note, the BCR-ABL1 transcript levels at the time of
restarting treatment were above the threshold of 5% IS in
only 7 cases, with this suggesting that an adequate mon-
itoring was performed in the setting of common clinical
practice. Indeed, disease resistance was not an issue in
patients who required TKI therapy due to molecular
relapse, in line with published data from clinical trials14.
Several findings on the evolution of the laboratory
parameters after TKI discontinuation deserve to be men-
tioned. At the time of treatment cessation, the Hb levels
and the leukocyte counts were significantly lower in
patients receiving imatinib than in those on nilotinib
treatment, with this suggesting a stronger myelosuppres-
sive effect of the former. In fact, a dose-dependent inhi-
bitory effect of imatinib on normal progenitor cells has
experimentally been demonstrated in vitro30 and in vivo31.
Table 3 Factors potentially associated with an increased risk of molecular relapse after discontinuation of TKI treatment
in CML
Covariate No. patients per group Subhazard ratio (95% CI) P-value
Sex (male vs. female) 113 / 123 1.05 (0.64–1.71) 0.83
Age (> 60 vs. ≤ 60 years) 125 / 111 1.03 (0.63–1.69) 0.87
Sokal risk index (high vs. low-intermediate) 17 / 198 1.54 (0.73–3.25) 0.25
BCR-ABL transcript type (e13a2 vs. e14a2) 70 / 104 0.78 (0.43–1.42) 0.43
History of TKI resistance (yes vs. no) 17 / 219 1.14 (0.43–3.06) 0.28
No. of TKI lines before discontinuation (> 1 vs. 1) 52 / 184 1.21 (0.67–2.2) 0.51
TKI at the time of discontinuation (imatinib vs. others) 175 / 61 0.77 (0.44–1.33) 0.35
Prior exposure to interferon (yes vs. no) 55 / 181 0.53 (0.28–1.01) 0.055
Duration of TKI treatment (< 5 years vs. ≥ 5 years) 19 /217 2.59 (1.33–5.01) 0.005
Time in MR4.5 before discontinuation (< 4 years vs. ≥ 4 years) 82 / 153 2.06 (1.27–3.35) 0.003
CI confidence interval, CML chronic myeloid leukemia, TKI tyrosine kinase inhibitor
Numbers in bold are those with a significant P-value on the statistical analysis (P < 0.05)
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In a previous study including CML patients who were in
DMR with imatinib 400mg daily, a dose reduction to
300mg daily resulted in a median Hb increase of 1 g/dL
among the anemic patients32. Our present data confirmed
that the myelosuppressive effect of long-term treatment
with imatinib is reversible, as patients stopping this drug
experienced a significant increase in all hematologic
values33. In particular, the increase in Hb levels observed
in anemic patients at 6 months from imatinib dis-
continuation (≥ 1 g/dL and ≥ 2 g/dL in 72% and 47% of
patients, respectively) might be of clinical significance, as
chronic fatigue has been identified as the most important
factor limiting health-related quality of life in patients on
long-term therapy with imatinib34. By contrast, nilotinib
withdrawal did not appear to have any major impact on
the hematologic values. With regard to the biochemical
parameters, patients who stopped imatinib had higher
serum creatinine levels at baseline, but experienced a
significant reduction in creatinine levels afterwards, in line
with previous reports suggesting that imatinib can
decrease glomerular filtration35,36. On the other hand, it is
well recognized the early onset hypercholesterolemia
induced by nilotinib37, with such effect being potentially
involved in the pathogenesis of the occlusive arterial
events associated with this drug38. Current guidelines
recommend a proactive approach towards controlling the
hyperlipidemia induced by nilotinib with lifestyle inter-
ventions and lipid-lowering therapies8. Despite such
recommendations, total cholesterol levels at the time of
TKI discontinuation were significantly higher in nilotinib-
treated patients than in those receiving imatinib (median
difference ~20mg/dL). Such situation changed completely
after TKI treatment discontinuation, as cholesterol levels
significantly increased following imatinib withdrawal. As a
result of this tendency, at 6 months after treatment dis-
continuation patients who stopped imatinib ended up with
total cholesterol levels that were significantly higher than
those of patients stopping nilotinib. In this sense, plasma
lipid levels have been reported to normalize within one
month of imatinib treatment in small case series39. Ima-
tinib has also been shown to delay the development of
atherosclerosis in experimental models40 and to induce the
regression of type 2 diabetes mellitus41. Consequently, the
potential influence of cessation of imatinib treatment in
the long-term risk of cardiovascular events needs to be
evaluated in future studies.
Several experts’ recommendations14–16,25,26 and formal
guidelines18,27 have recently been published focusing on
the selection of candidates for TKI discontinuation in
clinical practice. In general, there is consensus on the
need to define a minimum duration of TKI exposure and
DMR before treatment discontinuation is to be attempted.
However, significant differences in the thresholds for the
minimal duration of TKI exposure have been proposed,
ranging from 3 to 8 years. In our series, we observed that
shorter periods of both TKI treatment and MR4.5 before
TKI discontinuation were significantly associated with
increased risk of molecular recurrence, with the best
cutoffs for discrimination being at 5 years and 4 years,
respectively. Despite that, the predictive value of such
clinical factors to accurately identify non-relapsing
patients at the individual level was poor. Moreover,
when we compared the incidence of molecular relapse in
optimal candidates for TKI treatment discontinuation
according to the criteria from Hughes and Ross15 (58% of
patients in our series) with that of the remaining patients,
no difference was observed. In line with other authors16,
we think that the emphasis on defining minimal criteria
for discontinuation TKI therapy in clinical practice should
not overlook what rate of TFR would be acceptable for
each individual patient, depending on the specific TKI-
related risks and patient preferences.
In conclusion, the present results contribute to reassure
the safety of TKI treatment discontinuation in real-life
clinical practice, under close molecular monitoring.
Resolution of TKI-related toxicity might translate into a
potential health improvement for the patients. Special
attention should be paid to the increase in cholesterol
levels observed after imatinib discontinuation. Finally,
further studies addressing the biological factors under-
lying the mechanisms of disease control after TKI treat-
ment cessation are warranted.
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